health
2026 IMS | IASO Bio Presented FUCASO China Real-World Data

— In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms, FUCASO achieved a 95.9% objective response rate, a 77.2% CR/sCR rate,...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories

Dad says he went permanently blind
New York Post

I'm a woman in my 20s and I'm not have the sex I want. I know what's holding me back.
Slate

Millions of cancer cases are linked to 5 common infections: study
New York Post

45-year-old man died after ER sent him home without antibiotics, lawsuit says
OregonLive.com
19 Harmless Symptoms That Are Major Medical Red Flags
BuzzFeed